Eosinophilic Asthma

被引：69
作者：
Nelson, Ryan K. [1 ]
Bush, Andrew [2 ,3 ]
Stokes, Jeffrey [4 ]
Nair, Parameswaran [5 ,6 ]
Akuthota, Praveen [1 ]
机构：
[1] Univ Calif San Diego, Dept Med, Div Pulm Crit Care & Sleep Med, 9500 Gilman Dr,MC 7381, La Jolla, CA 92093 USA
[2] Royal Brompton Hosp, Dept Paediat Resp Med, London, England
[3] Imperial Sch Med, Natl Heart & Lung Inst, London, England
[4] Washington Univ, Sch Med, Dept Pediat, Div Allergy Immunol & Pulm Med, St Louis, MO 63110 USA
[5] McMaster Univ, Dept Med, Div Respirol, Hamilton, ON, Canada
[6] St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON, Canada
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE | 2020年 / 8卷 / 02期
基金：
美国国家卫生研究院;
关键词：
Asthma; Eosinophils; Aspirin-exacerbated respiratory disease; Endotypes; EXACERBATED RESPIRATORY-DISEASE; DOUBLE-BLIND; RHINOSINUSITIS-ASTHMA; CLUSTER-ANALYSIS; ALLERGIC-ASTHMA; URINARY LTE4; NASAL POLYPS; MEPOLIZUMAB; PLACEBO; PHENOTYPES;
D O I：
10.1016/j.jaip.2019.11.024
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
Asthma endotypes are constantly evolving. Currently, there are no universally accepted criteria to define endotypes. The T(H)2-high endotype can have either allergic or nonallergic underpinnings and is typically characterized by some degree of eosinophilic airway inflammation. Unbiased clustering analyses have led to the identification of pediatric and adult phenotypes characterized by T(H)2 inflammation and associated endotypes with eosinophilic inflammation. Aspirin-exacerbated respiratory disease has also long been recognized as a unique asthma phenotype. An approach to identify these groups with biomarkers and subsequently choose a targeted therapeutic modality, particularly in severe disease requiring biologic agents, is outlined. (C) 2019 American Academy of Allergy, Asthma & Immunology
引用
收藏
页码：465 / 473
页数：9
相关论文
共 91 条
  • [11] BROWN HM, 1958, LANCET, V2, P1245
  • [12] Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
    Castro, M.
    Corren, J.
    Pavord, I. D.
    Maspero, J.
    Wenzel, S.
    Rabe, K. F.
    Busse, W. W.
    Ford, L.
    Sher, L.
    FitzGerald, J. M.
    Katelaris, C.
    Tohda, Y.
    Zhang, B.
    Staudinger, H.
    Pirozzi, G.
    Amin, N.
    Ruddy, M.
    Akinlade, B.
    Khan, A.
    Chao, J.
    Martincova, R.
    Graham, N. M. H.
    Hamilton, J. D.
    Swanson, B. N.
    Stahl, N.
    Yancopoulos, G. D.
    Teper, A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26) : 2486 - 2496
  • [13] Reslizumab for Poorly Controlled, Eosinophilic Asthma A Randomized, Placebo-controlled Study
    Castro, Mario
    Mathur, Sameer
    Hargreave, Frederick
    Boulet, Louis-Philippe
    Xie, Fang
    Young, James
    Wilkins, H. Jeffrey
    Henkel, Timothy
    Nair, Parameswaran
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (10) : 1125 - 1132
  • [14] Which Factors Associated With Activated Eosinophils Contribute to the Pathogenesis of Aspirin-Exacerbated Respiratory Disease?
    Choi, Youngwoo
    Lee, Youngsoo
    Park, Hae-Sim
    [J]. ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2019, 11 (03) : 320 - 329
  • [15] International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
    Chung, Kian Fan
    Wenzel, Sally E.
    Brozek, Jan L.
    Bush, Andrew
    Castro, Mario
    Sterk, Peter J.
    Adcock, Ian M.
    Bateman, Eric D.
    Bel, Elisabeth H.
    Bleecker, Eugene R.
    Boulet, Louis-Philippe
    Brightling, Christopher
    Chanez, Pascal
    Dahlen, Sven-Erik
    Djukanovic, Ratko
    Frey, Urs
    Gaga, Mina
    Gibson, Peter
    Hamid, Qutayba
    Jajour, Nizar N.
    Mauad, Thais
    Sorkness, Ronald L.
    Teague, W. Gerald
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (02) : 343 - 373
  • [16] Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
    Chupp, Geoffrey L.
    Bradford, Eric S.
    Albers, Frank C.
    Bratton, Daniel J.
    Wang-Jairaj, Jie
    Nelsen, Linda M.
    Trevor, Jennifer L.
    Magnan, Antoine
    ten Brinke, Anneke
    [J]. LANCET RESPIRATORY MEDICINE, 2017, 5 (05) : 390 - 400
  • [17] The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease
    Comhair, Suzy A. A.
    Bochenek, Grazyna
    Baicker-McKee, Sara
    Wang, Zeneng
    Stachura, Tomasz
    Sanak, Marek
    Hammel, Jeffrey P.
    Hazen, Stanley L.
    Erzurum, Serpil C.
    Nizankowska-Mogilnicka, Ewa
    [J]. RESPIRATORY RESEARCH, 2018, 19 : 210
  • [18] Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma Effects Across a Broad Range of Eosinophil Counts
    Corren, Jonathan
    Weinstein, Steven
    Janka, Lindsay
    Zangrilli, James
    Garin, Margaret
    [J]. CHEST, 2016, 150 (04) : 799 - 810
  • [19] Improvement of asprinin-intolerant asthma by montelukast, a leukotriene antagonist -: A randomized, double-blink, placebo-controlled trial
    Dahlén, SE
    Malmström, K
    Nizankowska, E
    Dahlén, B
    Kuna, P
    Kowalski, M
    Lumry, WR
    Picado, C
    Stevenson, DD
    Bousquet, J
    Pauwels, R
    Holgate, ST
    Shahane, A
    Zhang, J
    Reiss, TF
    Szczeklik, A
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (01) : 9 - 14
  • [20] De Groot J C., 2016, ERJ Open Research, V2, P1, DOI 10.1183/23120541.00100-2015
12345678910